Generally, our study showed the following highlights: 1) FHL3 lead to PDAC progression; 2) FHL3 maintained tumor growth in pancreatic cancer; 3) FHL3 elevated EMT-TFs to promote EMT process through the TGFβ/Akt/GSK3β/ubiquitin pathways but not TGFβ/smad2/3/4 pathway (Figure 7). This evidence concerns the gene GSK3B and pancreatic neoplasm.